Market Report Source

Overview

Report Overview

The sexual disorder pharmacotherapy market is dominated by drugs indicated for erectile dysfunction which commands an estimated 78% of the total sexual disorder market valued at US$3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups such as in women with hypoactive sexual desire disorder and in male andropause. Furthermore, new drugs are on course to redefine the landscape of sexual medicine by offering novel therapies for premature ejaculation and specific desire-arousal disorders. Emerging drug treatments targeting the unmet needs of women with sexual disorders are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that the female sexual dysfunction sector may outperform those therapies indicated for male sexual disorders within a decade of availability. However, as a relatively young and controversial therapy area, new drugs for sexual disorders are subject to intense regulatory scrutiny and navigating through the drug approval process is challenging particularly for new sexual disorder indications, which is evident from recent market authorization setbacks for Proctor & Gamble’s Intrinsa for female hypoactive sexual desire disorder and Johnson & Johnson/Alza’s Dapoxetine for premature ejaculation. However, in this report, The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a dynamic, high-value therapy area estimated to exceed US$6.6 billion by 2012.

The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Table of Contents

CONTENTS
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Sexual Disorders
Sexual Disorders
Prevalence of Sexual Dysfunction

- Male Sexual Disorders
Sexual Desire Disorders
Male Erectile Dysfunction
Normal Erectile Function
Psychological Aspects of Male Erectile Dysfunction
Prevalence of Male Erectile Dysfunction
Therapeutics for Male Erectile Dysfunction
Priapism
Peyronie’s disease
Disorders of Ejaculation
Premature Ejaculation
Retarded Ejaculation
Retrograde Ejaculation

- Female Sexual Dysfunction
Prevalence of Female Sexual Dysfunction
Specific Female Sexual Dysfunction Disorders
Disorders of Desire
Disorders of Arousal
Disorders of Lubrication
Persistent Sexual Arousal Syndrome
Disorders of Orgasm
Pain Disorders
Dyspareunia
Vulvodynia
Vaginismus

Chapter 2 The Sexual Disorders Pharmacotherapy Market
Market Data Synopsis – Sexual Disorders
Sexual Disorders: Market Overview
Market Analysis for Sexual Disorder Pharmacotherapeutics
Testosterone Replacement
Erectile Dysfunction
Female Sexual Disorders

Male Sexual Disorders
Androgen Deficiency and Disorders of Desire
The Andropause
Product Market Analysis for Androgen Deficiency and Disorders of Desire
Columbia Labs/Ardana
Sales Estimates and Market Outlook
Organon
Sales Estimates and Market Outlook
Schering
Sales Estimates and Market Outlook
Solvay Pharmaceuticals
Sales Estimates and Market Outlook
Drugs in Research and Development for Androgen Deficiency and Andropause
Ascend Therapeutics
Ardana
GTx
Androgen Deficiency and Sarcopenia – A High-Growth Market Prospect
National Institute on Aging
Anastrozole/Testosterone
Androgen Supplementation
Testosterone and Human Growth Hormone
Zonagen
Future Considerations for Drugs to Treat Androgen Deficiencies Associated
with Sexual Disorders and Andropause
Erectile Dysfunction
Uprima/Ixense (Apomorphine) – Abbott/TAP Pharmaceuticals
Sales Estimates and Market Outlook
Levitra (Vardenafil) – Bayer/GlaxoSmithKline
Sales Estimates and Market Outlook
Cialis (Tadalafil) – Lilly/ICOS
Sales Estimates and Market Outlook
Viagra (Sildenafil); Caverject (Alprostadil) – Pharmacia/Pfizer
Sales Estimates and Market Outlook
Viridal/Edex (Alprostadil) – Schwarz
Sales Estimates and Market Outlook
Invicorp (Phentolamine Mesilate/Vasoactive Intestinal Polypeptide) – Senetek/Ardana
Sales Estimates and Market Outlook
MUSE (Alprostadil) – Vivus
Sales Estimates and Market Outlook
Pipeline Focus – Avanafil
Future Considerations and Market Outlook for Drugs to Treat Erectile Dysfunction
Pipeline Drugs and Market Prospects in the Sexual Disorder Market
Erectile Dysfunction Drug Pipeline
Prograf (Tacrolimus/FK506) – Astellas Pharma
Alprox-TD (Alprostadil) – NexMed/Schering
PT-141 – Palatin Technologies/King Pharmaceuticals

Emerging Sexual Disorder Therapy Areas
Premature Ejaculation
Neuronal Mechanism of Premature Ejaculation
Drugs in Development for Premature Ejaculation
Dapoxetine – ALZA/Johnson & Johnson
Investigational Drug – Pfizer
BIO301 – Enhance Biotech/Bioaccelerate
NM100061 – NexMed
Future Considerations and Market Outlook for Drugs to Treat
Premature Ejaculation

Female Sexual Disorders
A High-Growth Market Opportunity?
Drugs in Development for Female Sexual Disorders
Intrinsa (Testosterone Patch) – Proctor & Gamble Pharmaceuticals/Watson Pharma
Tostrelle (Testosterone Gel) – Cellegy Pharmaceuticals
Androgel (Testosterone Gel) – Beersheva Mental Health Center, Israel
LibiGel (Testosterone Gel) – Antares Pharma/Biosante Pharmaceuticals
PT-141 – Palatin Technologies/King Pharmaceuticals
Alista (Alprostadil); Testosterone MDTS – Vivus/Acrux
Femprox Cream (Alprostadil) – NexMed
Future Considerations and Market Outlook for Drugs to Treat
Female Sexual Dysfunction

Chapter 3 Drugs in Research and Development
Male Sexual Disorders
Research and Development Overview
Female Sexual Dysfunction
Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Sexual Disorders: Therapy Area Forecasts
Market Share of Male Sexual Disorder Market
Comparative Analysis: Product Sales
Prospect Mining
Androgen Deficiency/Testosterone Replacement
Erectile Dysfunction and Premature Ejaculation
Female Sexual Dysfunction
Therapy Area Forecasts: 2012 and 2020
Chapter 5 Report Synopsis
Male Sexual Disorders – Key Data Points
Female Sexual Disorders – Key Data Points
Reference Sources

List of Tables
Table 1.1 Male and Female Sexual Dysfunction Disorders
Table 1.2 Medical and Surgical Conditions Associated with Erectile Dysfunction
Table 1.3 Therapeutic Options for Erectile Dysfunction
Table 2.1 Global Sales (US$) & Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
Table 2.2 Marketed Drugs for Androgen Deficiency and Erectile Dysfunction, 2005
Table 2.3 Symptoms of Andropause 37
Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Striant, 2005-2012
Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Organon’s Androgen Replacement Therapy Products, 2005-2012
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Schering’s Andrology Product Portfolio, 2005-2012
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Androgel, 2005-2012
Table 2.8 Drugs in Development for Androgen Deficiency and Andropause, 2005
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Uprima/Ixense, 2005-2012
Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Levitra, 2005-2012
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Cialis, 2005-2012
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Erectile Dysfunction Product Portfolio, 2005-2012
Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Viridal/Edex, 2005-2012
Table 2.14 Estimated Sales (US$) and Annual Growth (%) of Invicorp, 2005-2012
Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Muse, 2005-2012
Table 2.16 Drugs in Development for Male Erectile Dysfunction, 2005
Table 2.17 Drugs in Development for Premature Ejaculation, 2005
Table 2.18 Drugs in Development for Female Sexual Dysfunction, 2005
Table 3.1 Drugs in Development for Male Androgen Deficiency and Andropause, 2005
Table 3.2 Drugs in Development for Male Erectile Dysfunction and Premature Ejaculation, 2005
Table 3.3 Drugs in Development for Female Sexual Dysfunction, 2005
Table 4.1 Global Market for Male Sexual Disorders (US$m), 2004-2012
Table 4.2 Therapy Area Forecasts for the Global Sexual Disorders Drug Market: 2012 and 2020

List of Figures
Figure 2.1 Estimated Sales (US$) and Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
Figure 2.2 Estimated Growth and Global Market Share of Leading Drugs for Male Sexual Disorders, 2005 & 2012
Figure 4.1 Therapy Area Forecasts for Male Testosterone Replacement and Erectile Dysfunction, 2005 & 2012 (US$m)
Figure 4.2 Market Share of Male Testosterone Replacement (Desire/Arousal Conditions) and Erectile Dysfunction Therapy Areas, 2005 & 2012
Figure 4.3 Comparative Analysis of Leading Testosterone Replacement Therapies and Erectile Dysfunction Products, 2004-2012 (US$m)
Figure 4.4 Key Testosterone Replacement Drug Prospects in the Development Pipeline, 2005
Figure 4.5 Key Erectile Dysfunction and Premature Ejaculation Drug Prospects in the Development Pipeline, 2005
Figure 4.6 Key Female Sexual Dysfunction Drug Prospects in the Development Pipeline, 2005